On April 16, 2026 Abbott today (NYSE: ABT) reported financial results for the first quarter ended March 31, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First-quarter sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis.
First-quarter GAAP diluted EPS of $0.61 and adjusted diluted EPS of $1.15, which excludes specified items and reflects growth of 6 percent.
On March 23, 2026, Abbott completed its acquisition of Exact Sciences, establishing the company as a leader in the oncology diagnostics market and adding a new high-growth vertical to Abbott’s portfolio.
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1.
Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.
In January, Abbott announced a collaboration with AtaCor Medical to develop a next-generation extravascular implantable cardioverter (EV-ICD) system designed to deliver defibrillation therapy to people living with life-threatening heart rhythms.
In February, Abbott announced positive early results from the VERITAS study that show clinically meaningful closure rates of the investigational Amulet 360 Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib).
In March, Abbott announced results from the FreeDM2 randomized controlled trial, demonstrating that people with Type 2 diabetes on basal insulin who used FreeStyle Libre achieved a 0.6% reduction in HbA1c and spent 2.5 more hours per day in the healthy glucose range compared to fingerstick monitoring.
"Our first-quarter results were aligned with our expectations to start the year," said Robert B. Ford, chairman and chief executive officer, Abbott. "The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year."

FIRST-QUARTER BUSINESS OVERVIEW

Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott’s Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

4,274

844

905

—

2,523

International

6,890

1,173

1,275

1,426

3,016

Total reported

11,164

2,017

2,180

1,426

5,539

% Change vs. 1Q25

U.S.

2.5

(11.6)

3.8

n/a

7.9

International

11.3

(1.5)

7.8

13.2

18.0

Total reported

7.8

(6.0)

6.1

13.2

13.2

Total reported excl. foreign exchange impact

3.8

(7.7)

2.5

9.0

8.1

Comparable sales growth

3.7

(7.7)

1.8

9.0

8.5

U.S.

2.5

(11.6)

2.0

n/a

8.7

International

4.6

(4.7)

1.6

9.0

8.3

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Nutrition

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total

Pediatric

Adult

U.S.

844

511

333

International

1,173

442

731

Total reported

2,017

953

1,064

% Change vs. 1Q25

U.S.

(11.6)

(13.0)

(9.2)

International

(1.5)

(2.6)

(0.9)

Total reported

(6.0)

(8.5)

(3.6)

Total reported excl. foreign exchange impact

(7.7)

(9.7)

(5.9)

Comparable sales growth

(7.7)

(9.7)

(5.9)

U.S.

(11.6)

(13.0)

(9.2)

International

(4.7)

(5.3)

(4.3)

Worldwide Nutrition sales decreased 6.0 percent on a reported basis and 7.7 percent on a comparable basis in the first quarter.

Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of several new products, are expected to contribute to improved volume growth over the course of the year.

Diagnostics*

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total

Core Laboratory

Cancer Diagnostics

Rapid/Molecular
Diagnostics

U.S.

905

347

93

465

International

1,275

925

3

347

Total reported

2,180

1,272

96

812

% Change vs. 1Q25

U.S.

3.8

4.5

n/a

(13.8)

International

7.8

9.5

n/a

2.8

Total reported

6.1

8.1

n/a

(7.4)

Total reported excl. foreign exchange impact

2.5

3.3

n/a

(9.6)

Comparable sales growth

1.8

3.3

13.4

(9.6)

U.S.

2.0

4.5

13.2

(13.8)

International

1.6

2.8

19.2

(2.7)

*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott’s Cancer Diagnostics business.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Worldwide Diagnostics sales increased 6.1 percent on a reported basis and increased 1.8 percent on a comparable basis.

Worldwide Core Laboratory Diagnostics results were driven by growth in the U.S., Europe and Latin America. Sales of Core Laboratory diagnostic tests increased on both a year-over-year and sequential basis.

Rapid and Molecular Diagnostics results reflect lower demand for respiratory virus tests due to a weaker respiratory virus season compared to the prior year.

Results in Cancer Diagnostics reflect Abbott’s acquisition of Exact Sciences, which closed on March 23, 2026. Growth in Cancer Diagnostics was driven by double-digit growth of Cologuard and sales of Cancerguard, a multi-cancer screening test that launched last year.

Established Pharmaceuticals

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

1,426

1,089

337

Total reported

1,426

1,089

337

% Change vs. 1Q25

U.S.

n/a

n/a

n/a

International

13.2

12.9

14.1

Total reported

13.2

12.9

14.1

Total reported excl. foreign exchange impact

9.0

9.4

7.9

Comparable sales growth

9.0

9.4

7.9

U.S.

n/a

n/a

n/a

International

9.0

9.4

7.9

Established Pharmaceuticals sales increased 13.2 percent on a reported basis and 9.0 percent on a comparable basis in the first quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 12.9 percent on a reported basis and 9.4 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions.

Medical Devices

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total

Rhythm
Management

Electro-

physiology*

Heart
Failure

Vascular

Structural
Heart*

Neuro-
modulation

Diabetes
Care

U.S.

2,523

339

378

292

291

224

177

822

International

3,016

345

410

97

486

354

66

1,258

Total reported

5,539

684

788

389

777

578

243

2,080

% Change vs. 1Q25

U.S.

7.9

11.5

13.7

11.4

8.6

(9.5)

0.7

9.8

International

18.0

22.9

19.6

25.2

10.0

25.2

27.2

16.6

Total reported

13.2

17.0

16.7

14.6

9.5

9.0

6.8

13.8

Total reported excl. foreign exchange impact

8.1

12.5

12.5

12.2

4.9

3.6

4.1

7.4

Comparable sales growth

8.5

12.5

12.5

12.2

4.9

6.8

4.1

7.4

U.S.

8.7

11.5

13.7

11.4

8.6

(3.6)

0.7

9.8

International

8.3

13.5

11.2

14.9

2.7

15.0

15.5

5.7

*Abbott’s Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on Jan. 1, 2026. As a result, $46 million of sales in the first quarter of 2025 were moved from Structural Heart to Electrophysiology.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Worldwide Medical Devices sales increased 13.2 percent on a reported basis and 8.5 percent on a comparable basis in the first quarter.

Sales growth in the quarter was led by double-digit growth in Electrophysiology, Heart Failure and Rhythm Management.

In Diabetes Care, sales of continuous glucose monitors grew 14.2 percent on a reported basis and 7.6 percent on a comparable basis.

Abbott’s Financial Guidance
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.

Abbott projects second-quarter 2026 adjusted diluted earnings per share of $1.25 to $1.31.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott’s results in accordance with GAAP.

Abbott Declares 409th Consecutive Quarterly Dividend
On Feb. 20, 2026, the board of directors of Abbott declared the company’s quarterly dividend of $0.63 per share. Abbott’s cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

(Press release, Abbott, APR 16, 2026, View Source [SID1234664428])

On April 15, 2026 Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, reported the closing of a $108 million Series C financing round. The round includes new investors RA Capital Management, Deep Track Capital, Osage University Partners (OUP), and BeOne Medicines, and participation from existing investors OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Proceeds from this financing enable us to advance our lead AKT1-selective inhibitor programs through Phase 1 clinical development for patients with cancer and rare diseases such as hereditary hemorrhagic telangiectasia," said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto. "We are grateful for the support from new and existing investors as we work to unlock the full potential of selective AKT1 inhibition and bring more effective and better tolerated treatment options to patients with significant unmet need."

Terremoto’s lead oncology program, TER-2013, is currently in Phase 1 clinical development for solid tumors harboring genetic alterations in PIK3CA, AKT, or PTEN, which are implicated in a significant proportion of cancers, including more than half of patients with HR-positive breast cancer. The company is also advancing TER-4480, a program targeting hereditary hemorrhagic telangiectasia (HHT), a rare, inherited bleeding disorder characterized by abnormal blood vessel formation and significant morbidity, with currently no approved therapies. TER-4480 is expected to enter the clinic later this year.

AKT is a key regulatory protein implicated in driving disease progression in both cancer and HHT. Among the three structurally similar isoforms (AKT1, AKT2, AKT3), AKT1 has been shown in preclinical studies to be the predominant disease driver, while AKT2 is linked to adverse effects such as rash and dysregulation of glucose homeostasis. While there has been considerable advancement of other PI3K/AKT pathway inhibitors, the efficacy of these treatments has often been limited by toxicities – primarily due to PI3Kα or AKT2 inhibition. Using advanced medicinal chemistry capabilities, Terremoto has developed a novel class of AKT1-selective inhibitors to overcome these limitations, aiming to achieve deeper and more durable treatment response with an improved tolerability profile.

(Press release, Terremoto Biosciences, APR 15, 2026, View Source [SID1234665003])

On April 15, 2026 Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, multi-mechanism approach to cancer treatment, reported a poster presentation on CLIO-8221 at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 (April 17-22, San Diego). CLIO-8221, currently being evaluated in an ongoing Phase 1 trial, is a first-in-class dual-payload ADC, engineered for targeted delivery of two payload classes, a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor, to HER2-expressing tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"CLIO-8221 is the first program from Callio’s dual-payload ADC pipeline to enter the clinic, just one year after our launch, underscoring our commitment to advancing innovative dual-payload ADCs for cancer. By combining two complementary anti-cancer payloads, CLIO-8221 may offer a new treatment option for patients whose cancers are resistant to existing single-payload Topo1 inhibitor-based ADCs," said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer of Callio Therapeutics. "Our preclinical studies support the high potency and enhanced tolerability of CLIO-8221, enabled by our next generation linker platform and ADC technologies, and we look forward to presenting these data at AACR (Free AACR Whitepaper)."

At AACR (Free AACR Whitepaper) 2026, Callio Therapeutics will present data that highlight the potential of CLIO-8221 as a therapeutic option for HER2-expressing cancers:

CLIO-8221 is a dual-payload ADC carrying a Topo1 inhibitor and an ATR inhibitor (DAR 4:4 ratio), selected to maximize anti-tumor efficacy and overcome Topo1 inhibitor resistance
CLIO-8221 uses proprietary linker and ADC technologies to reduce systemic toxicity and enable co-delivery of both payloads to drive strong tumor cell killing
CLIO-8221 demonstrated potent anti-tumor activity across varying HER2 expression levels and drove tumor regression after a single dose in both trastuzumab deruxtecan-sensitive and -insensitive models
CLIO-8221 has a broad therapeutic window with no toxicological findings observed at doses up to 70 mg/kg in NHP studies
Poster Presentation:

Title: Development of CLIO-8221: A HER2-targeted dual-payload ADC to address ADC resistance
Session Title: Session PO.ET02.03 – Antibody-Drug Conjugates and Linker Engineering 3
Date & Time: April 21, 2026, 9:00 AM – 12:00 PM PDT
Location: Poster Section 12
Poster Board Number: 5
Poster Number: 4427

A Phase 1 clinical trial (NCT07300943) for CLIO-8221 is ongoing in Australia and the United States, with Callio Therapeutics having received IND clearance from the U.S. Food and Drug Administration in March 2026. The IND is also under review by the China National Medical Products Administration, and the trial is expected to expand to multiple sites in China.

About CLIO-8221

HER2 is a clinically validated target for antibody-drug conjugates (ADCs), with multiple approved therapies demonstrating meaningful benefit across tumor types, however, most patients eventually progress on treatment despite retaining HER2 expression. Mechanistic resistance to cytotoxic payloads has emerged as a key reason for treatment failure. CLIO-8221 is a novel, first-in-class dual-payload ADC targeting HER2, designed to address this challenge.

CLIO-8221 delivers two mechanistically complementary payloads, a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor, directly to HER2-expressing tumors. While Topo1 inhibitors have shown strong clinical activity, activation of the DNA damage response following Topo1 inhibitor-induced replication stress represents a potential major driver of resistance. By simultaneously inhibiting Topo1 and blocking the DNA damage response through ATR inhibition, CLIO-8221 is engineered to overcome payload insensitivity and sensitize tumors to Topo1 inhibition. Developed using proprietary linker and ADC platform technologies, CLIO-8221 aims to maximize anti-tumor activity while reducing systemic toxicity, offering the potential for deeper and more durable responses in patients who have progressed on existing HER2-targeted therapies.

(Press release, Callio Therapeutics, APR 15, 2026, View Source [SID1234664427])

On April 15, 2026 Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported key leadership appointments, adding three seasoned industry executives to the Company to support the rapid advancement of vopimetostat, a highly potent and selective PRMT5 inhibitor, towards its first potential regulatory approval in pancreatic cancer. Matthew Gall has been appointed Chief Financial Officer, Yen-Ching Chua as Chief Development Operations Officer, and Janice Kapty, PhD as SVP, Corporate Strategy and Project Leadership.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Building on our longstanding scientific leadership and recent clinical progress, Tango has a unique opportunity with vopimetostat to bring a potentially paradigm-shifting treatment to patients with pancreatic and other cancers," said Malte Peters, MD, President and Chief Executive Officer. "In order to support our goal and drive Tango’s next phase of growth, we have strengthened our development, corporate strategy and finance leadership to accelerate and support our efforts in late-stage development and potential commercialization. I extend my gratitude to our prior Chief Financial Officer, Daniella Beckman, for her many contributions to Tango since its inception, including taking the Company public and leading multiple capital raises. We wish her well in future endeavors. We look forward to presenting key clinical data this year, including initial data from our combination trial with Revolution Medicines, Inc.’s RAS(ON) inhibitors."

Matthew Gall has been appointed Chief Financial Officer effective April 15, succeeding Daniella Beckman. Mr. Gall is a seasoned biotechnology executive with extensive finance, corporate development, strategic transaction and capital raising experience. Previously, he was Chief Financial Officer at Kalaris Therapeutics and iTeos Therapeutics, and held finance, business development and corporate strategy roles at Sarepta Therapeutics, Celgene Corporation and Gilead Sciences.

Yen-Ching Chua has been appointed Chief Development Operations Officer effective June 1, overseeing clinical operations including data management, as well as quality, clinical compliance and clinical sourcing. She brings deep global experience, having previously led clinical and development operations across complex global portfolios at Novocure, Debiopharm International, MorphoSys and Novartis.

In addition, Janice Kapty, PhD has been appointed SVP, Corporate Strategy and Project Leadership, effective April 15. In this role, she will be responsible for portfolio strategy, oversee the project management organization, and ensure strong project leadership for vopimetostat and portfolio therapies, including TNG456. Previously, Dr. Kapty led drug development teams at Arvinas, MorphoSys, Constellation Pharmaceuticals, Bristol Myers Squibb and Celgene Corporation.

(Press release, Tango Therapeutics, APR 15, 2026, View Source [SID1234664426])

On April 15, 2026 Boehringer Ingelheim and Zai Lab (NASDAQ: ZLAB; HKEX: 9688) reported a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The Phase Ib/II study will assess the safety, tolerability, and initial clinical activity of combining obrixtamig, Boehringer Ingelheim’s DLL3/CD3 T-cell engager, with zocilurtatug pelitecan (zoci; formerly ZL‑1310), Zai Lab’s DLL3-targeting ADC. The study will enroll patients with poorly differentiated NECs and extensive stage SCLC (ES-SCLC); diseases where patients urgently need more effective treatment options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The strategy to engage the immune system with a specific T‑cell engager and deliver a potent cytotoxic payload with a DLL3‑targeting ADC, aligns with our immuno‑oncology strategy and our drive to advance smart combinations for hard‑to‑treat cancers," said Itziar Canamasas, Ph.D., Global Head of Oncology at Boehringer Ingelheim. "It’s another step in our mission to expand effective options for people with DLL3‑expressing cancers."

"Zoci has shown encouraging activity and good tolerability in SCLC," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "We have rapidly advanced zoci into pivotal stage and are pursuing opportunities to explore multiple combination approaches in SCLC and other NECs. This collaboration with Boehringer Ingelheim offers a compelling DLL3‑targeting strategy with the potential to benefit patients who urgently need better treatments."

Obrixtamig is Boehringer Ingelheim’s investigational bispecific DLL3/CD3 T‑cell engager, designed to direct the body’s own immune cells to attack DLL3‑expressing cancer cells, a hallmark of SCLC and certain NECs. In the global Phase I first‑line ES‑SCLC study DAREON‑8, in combination with chemotherapy and atezolizumab, obrixtamig showed encouraging signs of early clinical efficacy and a manageable safety profile1. Obrixtamig is being evaluated across multiple global studies and is advancing into a global Phase III trial (DAREON‑Lung‑1, NCT07472517). The molecule has received FDA Fast Track Designation and Orphan Drug Designation from both the FDA and the European Commission for neuroendocrine carcinomas.

Zocilurtatug pelitecan is Zai Lab’s DLL3targeting ADC engineered to deliver a potent cytotoxic payload to DLL3positive tumor cells in ES-SCLC. Updated global Phase I results in previously treated ES-SCLC show strong and durable responses, including in patients with brain metastases, along with a favorable safety profile. On this basis, the program has advanced into a global Phase III registrational study. In addition to SCLC, zoci is being evaluated in NECs. Zoci has received FDA Orphan Drug Designation and FDA Fast Track Designation for the treatment of SCLC.

Under the terms of the agreement, Zai Lab will supply its DLL3‑targeting ADC for the study, while Boehringer Ingelheim will sponsor and oversee day‑to‑day clinical operations. Each company retains the rights to its respective assets.

(Press release, Boehringer Ingelheim, APR 15, 2026, View Source [SID1234664425])